Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 82, Issue 6, Pages 686-693Publisher
WILEY
DOI: 10.1038/sj.clpt.6100408
Keywords
-
Categories
Funding
- NCRR NIH HHS [P51 RR00165] Funding Source: Medline
- NIAID NIH HHS [P01 AI 49364] Funding Source: Medline
- NIDA NIH HHS [P30 DA 12121] Funding Source: Medline
Ask authors/readers for more resources
Development of an HIV/AIDS vaccine has been slow because classical approaches to vaccine development have not yielded a vaccine. Encouragingly, new approaches using recombinant viral vectors, DNA vaccines, and combinations of different vectors in heterologous prime/boost regimens are yielding vaccines capable of controlling virulent immunodeficiency virus challenges in non-human primate models. These new vaccines elicit T cells capable of recognizing and killing virus-infected cells. Brief synopses are given for six vaccines currently advancing in human trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available